| 7.92 |  +0.18 / +2.33% |
Data as of 4:00pm ET | Day’s Change |
| 7.92 |  0.00 / 0.00% |
Volume: 254.0K |
| 3 Buy-Rated Dividend Stocks: OKS, PDLI, RGR 11:42am / TheStreet.com | PDL BioPharma Issues Q2 Royalty Guidance Jun 11 / MotleyFool.com |
| PDL BioPharma Guides Higher 2Q Royalties - Analyst Blog Jun 13 / Zacks.com | PDL BioPharma Sues Genentech for Underpayment of Royalties Jun 11 / MotleyFool.com |
| Previous close | 7.74 |
| Today’s open | 7.72 |
| Day’s range | 7.70 - 7.94 |
| Volume | 1,984,830 |
| Average volume (3 months) | 1,765,679 |
| Market cap | $1.1B |
| Dividend yield | 7.58% |
| Earnings growth (last year) | +26.09% |
| Earnings growth (this year) | +13.23% |
| Earnings growth (next 5 years) | +17.00% |
| Revenue growth (last year) | +3.45% |
| P/E ratio | 5.0 |
| Price/Sales | 2.63 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| PBYIPuma Biotechnology I... | -0.33 | -0.84% |
| USNAUSANA Health Science... | +1.30 | +1.77% |
| SRPTSarepta Therapeutics... | +0.39 | +1.03% |
| TSROTESARO Inc | -2.74 | -7.07% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $0.54 |
| Annual revenue (last year) | $374.5M |
| Annual profit (last year) | $211.7M |
| Net profit margin | 56.52% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director John Peter McLaughlin |
VP, Chief Financial & Accounting Officer Peter S. Garcia, MBA |
Corporate headquarters Incline Village, Nevada |
.
